Elan Corporation, plc (ADR) (ELN), Perrigo Company (PRGO): Strange Biotech Bedfellows

Elan Corporation, plc (ADR) (NYSE:ELN)When I interviewed Alkermes Plc (NASDAQ:ALKS)‘ CEO Richard Pops last year, he described the relocation of the company’s headquarters to Ireland where taxes are lower after buying Elan Corporation, plc (ADR) (NYSE:ELN)‘s drug technology business as a “secondary feature of the transaction.” The extended-release technology, which complements Alkermes Plc (NASDAQ:ALKS)’ own platform, was what Alkermes Plc (NASDAQ:ALKS) was really after.

Fast forward to yesterday with the rest of Elan Corporation, plc (ADR) (NYSE:ELN) on the auction block, Perrigo Company (NYSE:PRGO) pulled the trigger for $16.50 in a cash plus stock deal. Unlike the Alkermes Plc (NASDAQ:ALKS)-Elan Corporation, plc (ADR) (NYSE:ELN) deal, Perrigo Company (NYSE:PRGO) – which sells generic over-the-counter medications, as well as some generic prescription drugs and pet medications — seems to have nothing in common with Elan Corporation, plc (ADR) (NYSE:ELN), which has essentially become a holding company for royalties from Biogen Idec Inc (NASDAQ:BIIB)‘s Tysabri after Elan Corporation, plc (ADR) (NYSE:ELN) spun off its research and development into Prothena Corporation PLC (NASDAQ:PRTA).

But there’s that tempting Ireland-based headquarters with its corporate tax of just 12.5%.

Perrigo Company (NYSE:PRGO) said it believes that the combined companies can save $150 million annually. Some of that will come from cutting salaries of the people left at Elan Corporation, plc (ADR) (NYSE:ELN), but much of it will come from tax savings from being located outside the U.S.

The new headquarters also gives Perrigo Company (NYSE:PRGO) a place to launch an international expansion. Moving into internal markets makes a lot of sense for generic drugs, where margins are much tighter than they are for branded drugs. Increasing scale can help expand margins since some costs are fixed. I’m not sure Perrigo Company (NYSE:PRGO) needed to buy a whole company just to get a global presence, but it’s certainly a shorter means to an end.

To justify the deal, Perrigo Company (NYSE:PRGO) needs more than just the Ireland headquarters. The royalties from Tysabri need to increase to justify the $8.6 billion price tag. You can go through the potential valuations, but I’m guessing that the fine folks at Royalty Pharma spent more time on it than you and I ever would and the fund was only willing to pay $15.50 per share, and that came with conditions of Tysabri reaching certain sales and development goals.

Admittedly, Royalty Pharma probably couldn’t get as much value (if any) from the Ireland headquarters as Perrigo can, but it certainly doesn’t look like Perrigo is getting a steal here.

Perrigo’s investors seem less than enthralled with the deal, sending shares down 7% yesterday. I really can’t blame them. The acquisition makes Perrigo more diversified, which can be a good thing, but in this case it also increases the risk. Perrigo is putting a lot of faith in what should be the primary feature of the transaction: Tysabri and Biogen Idec Inc (NASDAQ:BIIB)’s ability to continue increasing sales of the drug.

The article Strange Biotech Bedfellows originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!